CinCor Pharma, Inc. – NASDAQ:CINC

Add to watchlist

Market closed

Open in about 1 hour

+0.80%

month

+13.38%

quarter

+15.55%

year

Market Cap	1.27B
Enterprise value	N/A

P/E	-14.45
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	2.28
PEG ratio	N/A
EPS	-2.55

Revenue	N/A
EBITDA	-83.58M
Income	-93.31M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

CinCor Pharma, Inc. (NASDAQ:CINC): Profit margin
Dec 2021	0	-33.44M
Mar 2022	0	-19.63M
Jun 2022	0	-20.52M
Sep 2022	0	-19.71M

CinCor Pharma, Inc. (NASDAQ:CINC): Earnings per share (EPS)
2022-08-08	-0.5	-0.56
2022-11-03	-0.61	-0.51

CinCor Pharma, Inc. (NASDAQ:CINC): Debt to assets
Dec 2021	141106640	204.82M	145.16%
Mar 2022	321648077	5.68M	1.77%
Jun 2022	303015833	7.28M	2.4%
Sep 2022	529119088	10.18M	1.92%

CinCor Pharma, Inc. (NASDAQ:CINC): Cash Flow
Dec 2021	-11.02M	0	5.92M
Mar 2022	-17.71M	-149.83M	195.54M
Jun 2022	-19.55M	-17.42M	-3
Sep 2022	-15.11M	-63.22M	243.28M

CinCor Pharma alternative data

CinCor Pharma, Inc. (NASDAQ:CINC): Employee count
Aug 2023	19
Sep 2023	19
Oct 2023	19
Nov 2023	19
Dec 2023	19
Jan 2024	19
Feb 2024	19
Mar 2024	19
Apr 2024	19
May 2024	19
Jun 2024	19
Jul 2024	19

CinCor Pharma, Inc. (NASDAQ:CINC): Insider trades (number of shares)
Period	Buy	Sel
Jan 2022	4757450	0
Aug 2022	1905333	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	11 Jan 2023	PEARCE CATHERINE officer: Chief Operating Officer officer: Chief Operating Officer	Common Stock	13,235	N/A	N/A
Option	11 Jan 2023	PEARCE CATHERINE officer: Chief Operating Officer officer: Chief Operating Officer	Restricted Stock Units	13,235	N/A	N/A
Purchase	15 Aug 2022	5AM PARTNERS VI, LLC 10 percent owner 10 percent owner	Common Stock	487,333	$30	$14,619,990
Purchase	15 Aug 2022	5AM PARTNERS VI, LLC 10 percent owner 10 percent owner	Common Stock	112,667	$30	$3,380,010
Purchase	15 Aug 2022	SOFINNOVA PARTNERS SAS 10 percent owner 10 percent owner	Common Stock	133,333	$30	$3,999,990
Purchase	11 Aug 2022	HEALY JAMES director, 10 percent owner director, 10 percent owner	Common Stock	6,000	$30	$180,000
Purchase	11 Aug 2022	HEALY JAMES director, 10 percent owner director, 10 percent owner	Common Stock	500,000	$30	$15,000,000
Purchase	11 Aug 2022	SOFINNOVA VENTURE PARTNERS X, L.P. 10 percent owner 10 percent owner	Common Stock	500,000	$30	$15,000,000
Purchase	11 Aug 2022	GENERAL ATLANTIC, L.P. 10 percent owner 10 percent owner	Common Stock, par value $0.00001 per share ("Common Stock")	83,000	$30	$2,490,000
Purchase	11 Aug 2022	GENERAL ATLANTIC GENPAR (BERMUDA), L.P. 10 percent owner 10 percent owner	Common Stock, par value $0.00001 per share ("Common Stock")	83,000	$30	$2,490,000

CinCor Pharma
Latest News

Monday, 13 February 2023
09:23	There's a Lot to Love About Mineralys' Valentine's Day IPO	MarketBeat
Monday, 9 January 2023
10:42	Why Is CinCor (CINC) Stock Up 138% Today?	InvestorPlace
07:09	AstraZeneca to acquire CinCor for US$1.8bn	Proactive Investors
04:32	AstraZeneca to Buy CinCor Pharma in $1.8 Billion Deal	Barrons
02:16	AstraZeneca to buy U.S.-based CinCor Pharma in $1.8 bln deal	Reuters
Tuesday, 13 December 2022
22:55	These Were the 5 Best and Worst Performing Small-Cap Stocks in November 2022	24/7 Wall Street
Tuesday, 29 November 2022
13:32	CinCor (CINC) Tanks Due to Dismal Data on Hypertension Drug	Zacks Investment Research
Monday, 28 November 2022
08:52	CinCor's hypertension drug misses primary endpoint in mid-stage study	Market Watch
Tuesday, 22 November 2022
18:44	CinCor Pharma to Present at Upcoming Piper Sandler and Evercore ISI Investor Conferences	GlobeNewsWire
Wednesday, 16 November 2022
21:21	These Are the 10 Best-Performing IPOs in 2022 Through October	24/7 Wall Street
Wednesday, 31 August 2022
08:00	CinCor Pharma to Participate at Upcoming September Investor Conferences	GlobeNewsWire
Thursday, 9 June 2022
09:58	7 No-Brainer Biotech Stocks to Add to Your Buy List	InvestorPlace
Wednesday, 1 June 2022
12:20	CinCor Pharma Begins Patient Dosing In Midstage Hypertension, Kidney Disease Study	Benzinga
Tuesday, 31 May 2022
16:05	CinCor Pharma to Present at the Jefferies Healthcare Conference	GlobeNewsWire
Tuesday, 17 May 2022
16:05	CinCor Pharma to Present at Upcoming Investor Conferences	GlobeNewsWire
Tuesday, 15 March 2022
09:41	CinCor Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on March 22, 2022	GlobeNewsWire
Thursday, 3 March 2022
09:15	CinCor Pharma to Present at the 32nd Annual Oppenheimer Healthcare Conference	GlobeNewsWire
Thursday, 13 January 2022
07:47	10 Best Stocks to Buy on the Nasdaq Right Now	InvestorPlace
Saturday, 8 January 2022
23:36	U.S. IPO Weekly Recap: Biotechs Ring In The New Year In A 4 IPO Week	Seeking Alpha
Friday, 7 January 2022
15:26	The Year's First Three IPOs All Went 'Clunk.' This Is Why.	Barrons
13:36	Three Biotech IPOs Started Trading. Here's How the Stocks Did.	Barrons
11:21	CinCor Pharma's stock opens well above IPO price, then sells off sharply	Market Watch
08:42	CinCor Pharma raised $194 million as upsized IPO prices in middle of expected range	Market Watch
Tuesday, 4 January 2022
09:21	2022 IPO Market Kicks Off With 3 Biotechs Set To Trade On Friday	Seeking Alpha

Ideas & Opinions

Seeking Alpha 9 Jan 2022

U.S. IPO Weekly Recap: Biotechs Ring In The New Year In A 4 IPO Week

Frequently Asked Questions (FAQ)

When is CinCor Pharma's next earnings date?

Unfortunately, CinCor Pharma's (CINC) next earnings date is currently unknown.
Does CinCor Pharma pay dividends?

No, CinCor Pharma does not pay dividends.
How much money does CinCor Pharma make?

CinCor Pharma has a market capitalization of 1.27B. CinCor Pharma made a loss 50.35M US dollars in net income (profit) last year or -$0.51 on an earnings per share basis.
What is CinCor Pharma's stock symbol?

CinCor Pharma, Inc. is traded on the NASDAQ under the ticker symbol "CINC".
What is CinCor Pharma's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of CinCor Pharma?

Shares of CinCor Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does CinCor Pharma have?

As Jul 2024, CinCor Pharma employs 19 workers.
When CinCor Pharma went public?

CinCor Pharma, Inc. is publicly traded company for more then 3 years since IPO on 7 Jan 2022.
What is CinCor Pharma's official website?

The official website for CinCor Pharma is cincor.com.
Where are CinCor Pharma's headquarters?

CinCor Pharma is headquartered at 200 Clarendon Street, Boston, MA.
How can i contact CinCor Pharma?

CinCor Pharma's mailing address is 200 Clarendon Street, Boston, MA and company can be reached via phone at +84 45311834.

CinCor Pharma, Inc.

cincor.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. CinCor Pharma, Inc. has a license agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.

+84 45311834

200 Clarendon Street
Boston, MA 02116

CIK: 0001868734
ISIN: US17240Y1091
CUSIP: 17240Y109